Caris Life Sciences
Caris Life Sciences was founded because of an idea — that more precise and personalized health information can improve patients’ lives and ultimately improve healthcare for everyone. This drives everything we do, from developing a dynamic new cancer blood test for prostate cancer and other complex diseases, to providing evidence-based, customized chemotherapy treatment guidance for oncologists and their cancer patients. We offer molecular pathology lab services and comprehensive tumor profiling, and are developing cancer blood tests for earlier diagnosis of cancer.
Our efforts are focused on two primary technologies: Caris Target Now™ Molecular Pathology, Tumor Profiling and Evidence-Based Theranostics and Carisome™ Circulating Microvesicle (cMV) Technology.
Caris Target Now provides molecular pathology and tumor profiling services, coupled with evidence-based therapeutic guidance for cancer patients facing therapeutic uncertainty.
Carisome Circulating Microvesicle (cMV) Technology represents a revolution in blood-based diagnostic technologies. The technology is showing great potential for early detection and diagnosis of various cancers, as well as other complex diseases.
Caris employs a talented team of leading molecular pathology experts, histologists, molecular geneticists, lab technicians and other medical professionals. Our commitment to scientific excellence drives our hiring decisions and informs everything we do.
Pathology Services
Caris AP Business Joins Miraca Holdings
Caris Life Sciences’ anatomic pathology business and its subsidiaries and affiliates (operated by Caris Diagnostics, Inc.) is now officially part of Miraca Holdings, Inc. Read more.
More about Pathology Services.
Find a Doctor
Find a local doctor who can help you determine if Caris Target Now might be right for you.
